| Title |
Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, December 2009
|
| DOI | 10.2147/tcrm.s4483 |
| Pubmed ID | |
| Authors |
Pauline Byakika-Kibwika, Mohammed Lamorde, Harriet Mayanja-Kizza, Concepta Merry, Bob Colebunders, Jean-Pierre Van geertruyden |
| Abstract |
Artemether-lumefantrine is one of the artemisisnin-based combination therapies recommended for treatment of uncomplicated falciparum malaria. The drug combination is highly efficacious against sensitive and multidrug resistant falciparum malaria. It offers the advantage of rapid clearance of parasites by artemether and the slower elimination of residual parasites by lumefantrine. The combination can be used in all populations except pregnant mothers in the first trimester where safety is still uncertain. There are still concerns about safety and pharmacokinetics of the drug combination in children, especially infants, pregnant mothers and drug interactions with mainly non-nucleoside reverse transcriptase inhibitors and protease inhibitors used for HIV therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 3% |
| United Kingdom | 1 | 1% |
| Switzerland | 1 | 1% |
| Tanzania, United Republic of | 1 | 1% |
| Unknown | 62 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 16% |
| Student > Bachelor | 9 | 13% |
| Student > Ph. D. Student | 8 | 12% |
| Student > Master | 6 | 9% |
| Student > Doctoral Student | 5 | 7% |
| Other | 14 | 21% |
| Unknown | 14 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 33% |
| Agricultural and Biological Sciences | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Nursing and Health Professions | 2 | 3% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 11 | 16% |
| Unknown | 16 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2015.
All research outputs
#5,446,629
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#275
of 1,323 outputs
Outputs of similar age
#28,983
of 176,936 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 10 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,936 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.